Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.

Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.

Show other versions (1)

<h4>Background/objective</h4>AUGUSTUS trial demonstrated that, for patients with atrial fibrillation (AF) having acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI), an antithrombotic regimen with apixaban and P2Y12 resulted in less bleeding, fewer hospit...

Full description

Saved in:
Bibliographic Details
Main Authors: Simone Rivolo, Manuela Di Fusco, Carlos Polanco, Amiee Kang, Devender Dhanda, Mirko Savone, Aristeidis Skandamis, Thitima Kongnakorn, Javier Soto
Format: article
Language:EN
Published: Public Library of Science (PLoS) 2021
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/278fdc84cdba4d2a9fd177cbad4f1a2c
Tags: Add Tag
No Tags, Be the first to tag this record!
Search Result 1
Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain
Get full text
article
Save to List
Saved in:
Show all versions (2)

Similar Items